V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10002905 | 10001878 | 0 | 60.4 | Palliative (P) | 2013-08-17 | 2013-08-18 | Cisplatin + Pemetrexed | N | N | 10451946 | CISPLATIN + PEMETREXED |
| 10002906 | 10006303 | 1.84 | 67.8 | Adjuvant (A) | 2018-03-06 | 2018-03-09 | R GCVP | 02 | Y | 10451970 | CVP R |
| 10002907 | 10008033 | 1.8 | 73.3 | Palliative (P) | 2016-09-11 | 2016-09-16 | PEMBROLIZUMAB | N | N | 10452056 | PEMBROLIZUMAB |
| 10002908 | 10001879 | 1.66 | 76 | Palliative (P) | 2018-10-07 | 2018-10-07 | CVP R | 02 | N | 10452398 | CVP R |
| 10002909 | 10001880 | 1.73 | 72.4 | Neo-adjuvant (N) | 2017-09-11 | 2017-09-15 | Trial Unspecified | Y | N | 10452407 | TRIAL |
| 10002910 | 10001881 | 1.73 | 65.9 | Palliative (P) | 2018-05-25 | 2018-05-28 | PEMBROLIZUMAB | 2 | N | 10452411 | PEMBROLIZUMAB |
| 10002911 | 10001881 | 1.75 | 87.6 | Disease modification (D) | 2018-12-28 | 2018-12-28 | Hydroxycarbamide | N | null | 10452411 | HYDROXYCARBAMIDE |
| 10002912 | 10001882 | 1.82 | 72 | Palliative (P) | 2015-02-15 | 2015-02-25 | PEMBROLIZUMAB | 02 | N | 10452493 | PEMBROLIZUMAB |
| 10002913 | 10001883 | 1.75 | 72.7 | Not known (9) | 2015-09-19 | 2015-09-30 | CVP R | N | N | 10452498 | CVP R |
| 10002914 | 10001884 | 0 | 74.45 | Adjuvant (A) | 2016-06-17 | 2016-06-17 | Hydroxycarbamide | 2 | N | 10452508 | HYDROXYCARBAMIDE |
| 10002915 | 10001885 | null | 73.7 | Neo-adjuvant (N) | 2014-01-23 | 2014-01-30 | EOX | null | N | 10452575 | EOX |
| 10002916 | 10001885 | 1.7 | 101.9 | Palliative (P) | 2017-02-03 | 2017-02-03 | Hydroxycarbamide | N | N | 10452575 | HYDROXYCARBAMIDE |
| 10002917 | 10001886 | 1.7 | 74 | Neo-adjuvant (N) | 2017-06-30 | 2017-07-05 | ECX | N | null | 10452601 | ECX |
| 10002918 | 10001886 | 1.78 | 78.8 | Palliative (P) | 2016-09-26 | 2016-09-29 | Enzalutamide | N | N | 10452601 | ENZALUTAMIDE |
| 10002919 | 10008034 | 1.6 | 64.5 | Disease modification (D) | 2018-11-09 | 2018-12-02 | Trial Unspecified | 01 | N | 10452711 | TRIAL |
| 10002920 | 10001887 | 1.53 | 45 | null | 2018-11-01 | 2018-11-11 | Rituximab | N | N | 10452742 | RITUXIMAB |
| 10002921 | 10001888 | 0 | 49 | Palliative (P) | 2016-12-15 | 2016-12-28 | PEMBROLIZUMAB | 2 | N | 10452769 | PEMBROLIZUMAB |
| 10002922 | 10001889 | 1.7 | 80.45 | Palliative (P) | 2019-03-02 | 2019-03-02 | Enzalutamide | N | N | 10452775 | ENZALUTAMIDE |
| 10002923 | 10001890 | 1.61 | 83.2 | Disease modification (D) | 2019-06-26 | 2019-07-28 | R GCVP | 02 | N | 10452780 | CVP R |
| 10002924 | 10006307 | 1.63 | 73.1 | Palliative (P) | 2013-11-30 | 2013-11-30 | Rituximab (Maintenance) | N | null | 10452862 | RITUXIMAB |
| 10002925 | 10006307 | 1.68 | 74 | Palliative (P) | 2016-12-01 | 2017-01-17 | Cisplatin + Pemetrexed | N | N | 10452862 | CISPLATIN + PEMETREXED |
| 10002926 | 10006307 | 1.54 | 49.3 | Neo-adjuvant (N) | 2017-10-19 | 2017-10-19 | ECX | N | N | 10452862 | ECX |
| 10002927 | 10009091 | 1.8 | null | Palliative (P) | 2018-08-20 | 2018-08-30 | CVP R | N | Y | 10453029 | CVP R |
| 10002928 | 10001891 | 1.7 | 0 | Palliative (P) | 2007-12-08 | 2013-06-05 | CVP R | 02 | N | 10453129 | CVP R |
| 10002929 | 10001892 | 1.55 | 55 | Palliative (P) | 2018-09-13 | 2018-09-29 | EOX | N | N | 10453140 | EOX |
| 10002930 | 10001892 | 1.67 | 81 | Palliative (P) | 2017-02-10 | 2017-02-17 | Enzalutamide | 02 | N | 10453140 | ENZALUTAMIDE |
| 10002931 | 10001892 | 1.75 | 71.2 | Palliative (P) | 2016-08-29 | 2016-09-26 | Gemcitabine 1000mg/m2 D1 8 15 | N | N | 10453140 | GEMCITABINE |
| 10002932 | 10001892 | 1.7 | 100.8 | Palliative (P) | 2017-08-03 | 2017-08-03 | PEMBROLIZUMAB | 02 | N | 10453140 | PEMBROLIZUMAB |
| 10002933 | 10001892 | 1.58 | 86 | Palliative (P) | 2014-11-20 | 2014-11-25 | CVP R | 2 | N | 10453140 | CVP R |
| 10002934 | 10001893 | 1.57 | 51.4 | Curative (C) | 2017-03-17 | 2017-03-29 | Cisplatin + Vinorelbine (PO) | 2 | N | 10453798 | CISPLATIN + VINORELBINE |
| 10002935 | 10001893 | null | 75.6 | Palliative (P) | 2016-07-14 | 2016-07-15 | Enzalutamide | N | N | 10453798 | ENZALUTAMIDE |
| 10002936 | 10001894 | null | null | Palliative (P) | 2013-10-30 | 2013-11-04 | Cisplatin + Pemetrexed | 02 | N | 10453808 | CISPLATIN + PEMETREXED |
| 10002937 | 10001895 | null | 84.4 | Disease modification (D) | 2013-09-24 | 2013-09-24 | Hydroxycarbamide | N | null | 10453839 | HYDROXYCARBAMIDE |
| 10002938 | 10001896 | 1.75 | 77 | Not known (9) | 2018-04-09 | 2018-04-09 | EOX | 2 | N | 10453910 | EOX |
| 10002939 | 10001897 | 1.63 | null | Palliative (P) | 2015-01-28 | 2015-02-17 | PEMBROLIZUMAB | 02 | N | 10453926 | PEMBROLIZUMAB |
| 10002940 | 10001898 | 1.83 | 97.6 | Palliative (P) | 2018-09-10 | 2018-09-17 | Carboplatin + Vinorelbine IV | 02 | N | 10453986 | CARBOPLATIN + VINORELBINE |
| 10002941 | 10001899 | 1.81 | 63.7 | Palliative (P) | 2014-11-22 | 2014-11-29 | Cisplatin + Pemetrexed | null | N | 10453996 | CISPLATIN + PEMETREXED |
| 10002942 | 10001900 | null | 88.9 | Palliative (P) | 2014-01-22 | 2014-01-28 | EOX | N | null | 10453997 | EOX |
| 10002943 | 10006310 | 1.68 | 67 | Neo-adjuvant (N) | 2016-03-03 | 2016-03-22 | Carboplatin + Vinorelbine Oral | N | N | 10454032 | CARBOPLATIN + VINORELBINE |
| 10002944 | 10001901 | 1.67 | 0 | Adjuvant (A) | 2017-03-22 | 2017-04-07 | Cisplatin + Vinorelbine (IV) | N | N | 10454085 | CISPLATIN + VINORELBINE |
| 10002945 | 10006311 | null | 67.5 | Disease modification (D) | 2017-07-09 | 2017-07-11 | Hydroxycarbamide | N | N | 10454120 | HYDROXYCARBAMIDE |
| 10002946 | 10006311 | 1.71 | 63.9 | Palliative (P) | null | 2018-01-08 | Cisplatin + Pemetrexed | 2 | N | 10454120 | CISPLATIN + PEMETREXED |
| 10002947 | 10001902 | 1.75 | 0 | Adjuvant (A) | 2018-01-23 | 2018-01-28 | CARBOPLATIN + VINORELBINE | 02 | null | 10454157 | CARBOPLATIN + VINORELBINE |
| 10002948 | 10006312 | 1.69 | 92.1 | Palliative (P) | 2018-01-24 | 2018-01-27 | PEMBROLIZUMAB | N | N | 10454221 | PEMBROLIZUMAB |
| 10002949 | 10001903 | 1.75 | 82.6 | Disease modification (D) | 2018-11-09 | 2018-11-09 | Hydroxycarbamide | N | N | 10454359 | HYDROXYCARBAMIDE |
| 10002950 | 10001904 | 1.83 | 76 | Adjuvant (A) | 2018-08-08 | 2018-08-08 | Carboplatin + Vinorelbine IV &PO D8 | 02 | null | 10454422 | CARBOPLATIN + VINORELBINE |
| 10002951 | 10001904 | null | 59 | Palliative (P) | 2017-10-21 | 2017-10-21 | Trial Unspecified | Y | N | 10454422 | TRIAL |
| 10002952 | 10001904 | 1.8 | 0 | Palliative (P) | 2018-05-23 | 2018-05-24 | EOX | N | N | 10454422 | EOX |
| 10002953 | 10001905 | null | 115.3 | Palliative (P) | null | 2017-10-04 | Cisplatin + Pemetrexed | 2 | N | 10454494 | CISPLATIN + PEMETREXED |
| 10002954 | 10001906 | 1.72 | 106.7 | Adjuvant (A) | 2017-01-16 | 2017-01-24 | CARBOPLATIN + VINORELBINE | N | N | 10454495 | CARBOPLATIN + VINORELBINE |